Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470491 | 1.00 | ALDH1A1 (0.43) | ALDH1A1MGLLHRH3ACHEOPRM1 | |
| SCHEMBL5478489 | 1.00 | ALDH1A1 (0.43) | ALDH1A1MGLLHRH3ACHEOPRM1 | |
| SCHEMBL5473407 | 0.89 | YAP1 (0.45) | ALDH1A1MGLLOPRM1OPRK1KDM4E | |
| SCHEMBL5473403 | 0.89 | YAP1 (0.45) | ALDH1A1MGLLOPRM1OPRK1KDM4E | |
| SCHEMBL5473628 | 0.89 | YAP1 (0.45) | ALDH1A1MGLLOPRM1OPRK1KDM4E | |
| SCHEMBL5469243 | 0.89 | KMT2A (0.48) | ALDH1A1MGLLCYP2D6KDM4EKMT2A | |
| SCHEMBL5469237 | 0.89 | KMT2A (0.48) | ALDH1A1MGLLCYP2D6KDM4EKMT2A | |
| SCHEMBL5469239 | 0.89 | KMT2A (0.48) | ALDH1A1MGLLCYP2D6KDM4EKMT2A | |
| SCHEMBL4882462 | 0.85 | KMT2A (0.57) | ALDH1A1MGLLCYP2D6KDM4EKMT2A | |
| SCHEMBL4882471 | 0.85 | KMT2A (0.57) | ALDH1A1MGLLCYP2D6KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1679069-A1 | NOVEL PIPERIDINE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | LDLR, PRMT5, MSR1 | ALDH1A1 2990/4885MGLL 1254/4885HRH3 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.